What Valenta Pharm does

Valenta Pharm (AO Valenta Pharm / АО «Валента Фарм») is a Russian pharmaceutical company founded in 1997 and headquartered in Moscow. The company develops, manufactures, and markets both prescription and over-the-counter drugs across multiple therapeutic areas including psychoneurology, gastroenterology, cough and cold, antihistamines, antibacterial therapy, and women's health. It operates one of the largest high-tech pharmaceutical manufacturing facilities in Eastern Europe at its Scientific and Production Complex in Shchyolkovo, Moscow Oblast, producing approximately 100 million packages of finished dosage forms annually, with GMP and GDP certifications covering Russian regulatory standards.

The company's R&D capability covers the full original-drug development lifecycle — from high-potential molecule discovery through preclinical and clinical research to manufacturing and market launch — supplemented by collaborative development partnerships with European and Asian pharmaceutical developers and academic research relationships, including with George Mason University. Its branded portfolio spans flagship OTC assets such as Grammidin® (throat pain), Ingavirin® (antiviral), and the Multiplast® plaster line; prescription neuropsychiatric brands including Phenazepam® and Fenotropil®; antibacterial products such as Dioxidin® and Zitrolid®; the novel anti-inflammatory Atheriksen® (registered for COVID-19 in Russia in 2022); and women's-health and pediatric lines including Duonika®, 9 months, Moistana®, Fertina/Fertifolin, and Krokha lab® baby cosmetics.

Valenta distributes its products through three principal channels: a medical-representative field-sales force that addresses the hospital segment via state tenders under ФЗ-44 and ФЗ-223, key-account relationships with Russian pharmacy chains for OTC distribution, and direct-to-consumer e-commerce through Wildberries, Ozon, and other marketplaces. Operating geography is anchored in Russia, with extension into CIS markets including Kazakhstan, Uzbekistan, Belarus, and Armenia. The company employs between 101 and 250 staff and ranks among the TOP-5 Russian pharmaceutical companies and on Forbes Russia's TOP-20 (2026), with no publicly disclosed ownership structure or external funding.

Name

Valenta Pharm

Legal name

Акционерное общество «Валента Фармацевтика» (JSC Valenta Pharm)

Website

https://valentapharm.com

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

101–250 employees

Short description

Russian pharmaceutical company founded in 1997 that develops and manufactures branded prescription and OTC drugs across psychoneurology, gastroenterology, cold and cough, antibacterial, and women's health therapy areas, operating one of Eastern Europe's largest pharma production facilities with annual output of roughly 100 million packages distributed via pharmacy chains, hospital tenders, and online marketplaces.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)

akta.pro secondary industries

OTC Medicines & Consumer Health Products Distribution (CRAOAHAB), Pharmacy Front-End & Sundries Distribution (Health & Wellness, Personal Care, Convenience) (CRAOAHAG)

Keywords

• Prescription pharmaceuticals
• Over-the-counter drugs
• Original drug development
• Pharmaceutical manufacturing
• GMP certified production

Headquarters

HQ city

Moscow

HQ country

Russia

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Prescription Drugs: Sale of prescription pharmaceutical products including neuropsychiatry, gastroenterology, and antibacterial medications to hospitals and healthcare institutions via tender procurement
2. Over-the-Counter (OTC) Drugs: Sale of non-prescription drugs including cold remedies, antihistamines, and plaster products through pharmacy chains and marketplaces
3. R&D and Licensing: Collaborative development partnerships with European and Asian developers, with potential for licensing of innovative products

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Valenta Pharm is a Russian pharmaceutical company that develops, manufactures, and markets prescription and OTC drugs across therapeutic areas including neuropsychiatry, gastroenterology, anti-cold therapy, antibacterial treatment, women's health, and antihistamines. The company operates one of the largest high-tech pharmaceutical production facilities in Eastern Europe, producing approximately 100 million packages of finished dosage forms annually, with full-cycle R&D from preclinical and clinical research through production and market launch.

Product overview

Valenta Pharm is a Russian innovative pharmaceutical company founded in 1997, developing and manufacturing both prescription and over-the-counter drugs. The company operates across multiple therapeutic areas including psychoneurology (Феназепам®, Fenotropil®), cough & cold (Граммидин®, Ингавирин®), gastroenterology, antihistamines, and antibacterial therapy (Dioxidin®, Zitrolid®). Its product portfolio also includes medical devices (Multiplast® plasters for antibacterial, retention, corn, and children's use) and women's health products (Duonika®, 9 months, Moistana®, Fertina/Fertifolin). The company also produces baby cosmetics under the Krokha lab® brand. As one of the largest high-tech pharmaceutical manufacturers in Eastern Europe, Valenta Pharm produces approximately 100 million packages of finished medicinal products annually across socially significant pharmacotherapeutic groups.

Differentiator

Problem solved

Functional benefit

Brands

• Grammidin: Brand for sore throat treatment products including Grammidin Neo, Grammidin with anesthetic, and Grammidin children's formulas.
• Multiplast
• Fenazepam
• Krokha Lab
• 9 months
• Duonika
• Fertina and Fertifolin

Products and services

• Grammidin® (Граммидин) Throat pain relief medication, one of the leading brands in the sore throat category in Russia, marketed as an OTC product for consumers.
• Phenazepam® (Феназепам) Bromodihydrochlorophenylbenzodiazepine-based neuropsychiatric prescription medication for anxiety and related conditions.
• Ingavirin® (Ингавирин) Antiviral medicine for treating flu and ARVI in adults and children, sold as an OTC product.
• Atheriksen® (Атериксен) Unique Russian prescription drug for proactive anti-inflammatory therapy; registered in Russia in 2022 for treatment of mild COVID-19 in adults.
• Multiplast® Antibacterial Plasters Antibacterial plasters for wound care, featuring chlorhexidine bigluconate impregnated pads, for consumer wound care use.
• Multiplast® Retention Plasters Natural plaster tapes for secure retention of dressings, intended for medical and consumer use.
• Multiplast® Corn Plaster Plasters intended for treatment of dry corns and callosities, sold to consumers.
• Multiplast® Kids Children's plasters with hypoallergenic, breathable design and colorful graphics for minor injuries.
• Dioxidin® (Диоксидин) Prescription antibacterial medication active against microorganisms resistant to other antimicrobial agents including antibiotics.
• Zitrolid® (Зитролид) Azithromycin-based (500 mg capsules) prescription antibacterial medication for respiratory, skin, and urinary tract infections.
• Krokha lab® (Кроха lab) Professional dermatological cosmetics line for children from first day of life, featuring emollients with vioceramides, bisabolol, and phytosterol.
• 9 Months (9 месяцев) Line of products for pregnant women, supporting women's health across pregnancy stages.
• Moistana® (Моистана) Hydrating products for women's intimate health, sold to consumers.
• Duonika® (Дуоника) The only drug in the Russian Federation for treatment of nausea and vomiting in pregnant women; prescription product.
• Fertina and Fertifolin Dietary supplements for women's reproductive health containing inositol and folate, for pregnancy planning and reproductive support.

Quantifiable outcome

• TOP-5 Russian pharmaceutical company ranking
• +1 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• European and Asian pharmaceutical developerscoreStrategic or Co-development PartnerLeading foreign developers from Europe and Asia participate in developing new promising products for Valenta's portfolio. Development is conducted according to international quality standards for drug development and manufacturing.
• George Mason University (USA) - Ancha BaranovacoreStrategic or Co-development PartnerAcademic research partnership for Atheriksen® drug. Professor Ancha Baranova from George Mason University's School of Systems Biology co-authored the article published in Frontiers in Pharmacology.
• Russian and international medical organizationscoreStrategic or Co-development PartnerCollaborations with Russian and foreign organizations distinguished by professionalism and extensive expertise in research and development for creating innovative drugs and technological solutions.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Pharmstandard: Russia's largest domestic pharmaceutical manufacturer; produces branded prescription and OTC drugs, operates its own manufacturing, and competes head-to-head with Valenta in neuropsychiatry, antivirals, and OTC categories including tender-driven hospital supply.
• Vertex (Veropharm): Vertically integrated Russian pharmaceutical manufacturer with branded generics and OTC presence across similar therapeutic areas (respiratory, gastroenterology, neurology) and comparable hospital/pharmacy distribution channels.
• Akrikhin: Russian pharmaceutical manufacturer ranked similarly in domestic top pharma lists with branded generics and OTC in dermatology, respiratory, and women's health; competes with Valenta in pharmacy retail and government tender channels.
• OTCPharm: Russia-focused OTC consumer health company with a comparable brand-led marketing model (TV, influencer) and category leadership in cough/cold and sore throat, directly competing with Valenta's Grammidin franchise.

Broad incumbents

• STADA Arzneimittel AG: Global generics and consumer health major with deep established Russian OTC portfolio through its local subsidiary; offers overlapping sore throat, cold/flu, and dermatology lines and competes broadly in the same pharmacy shelves as Valenta.
• KRKA: Slovenian-headquartered generics manufacturer with strong Eastern European and CIS distribution; competes with Valenta in prescription generics, gastroenterology, and respiratory categories across shared regional markets.
• Sanofi: Global pharmaceutical major with established Russian prescription and OTC business; overlaps with Valenta in respiratory, allergy, gastroenterology, and women's health, though multinational presence has been impacted by geopolitical shifts.
• Bayer Consumer Health: Multinational OTC and consumer health leader active in Russia with categories (cold/flu, analgesics, dermatology) directly overlapping Valenta's OTC portfolio, including mass-market pharmacy presence.

Emerging players

• Polysan: Russian branded pharmaceutical developer focused on original drugs and anti-infectives; similar R&D-driven original-drug positioning that overlaps with Valenta's branded prescription portfolio and hospital segment.
• Grotex: Russian pharmaceutical manufacturer building branded and OTC presence, especially in women's health and consumer health categories that intersect with Valenta's Duonika, 9 months, and Fertina/Fertifolin lines.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/Valenta-Pharm-105860658024837
• LinkedInlinkedin.com/company/valenta-pharm

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Valenta Pharm